Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (DFG priority program 1937 (project SCHU 2326/2-1))
Received: 9 April 2018
Accepted: 24 January 2020
First Online: 26 February 2020
: The authors declare competing financial interests. The E.V. laboratory is supported by the European Research Council (ERC) under the “European Union’s Horizon 2020 research and innovation program (Grant agreement no. 694502)”, Agence Nationale de la Recherche, Innate Pharma, MSDAvenir, Ligue Nationale contre le Cancer (Equipe labelisée “La Ligue”) and Marseille-Immunopole. E.V. is cofounder, shareholder, and employee of Innate Pharma.